Abstract
Hepatitis-C virus (HCV) is an enveloped RNA virus that currently infects more than 180 million people, worldwide. Interferon therapy was previously used as a standard therapy for HCV. Now it has been replaced with an interferon-free therapy or the direct acting antiviral (DAA) drug therapy. Although the DAA drug therapy is a potent strategy which has an excellent efficacy against the HCV infection with a majority of patients achieving sustained virological response (SVR), we report here three patients who experienced relapse after a 6-month long DAA drug therapy. The patients experienced relapse after receiving sofosbuvir (400mg) and ribavirin for 6 months. All three patients were later successfully treated with sofosbuvir, ribavirin, and daclatasvir combination. The current study highlights that the retreatment combination of sofosbuvir, ribavirin, and daclatasvir is more efficacious in the Pakistani population where practitioners are still using sofosbuvir and ribavirin.
Highlights
The annual estimated global bioburden of Hepatitis C virus (HCV) is approximately 130 to 170 million infected people
Hepatitis-C virus (HCV): hepatitis C virus; DDA: direct acting antiviral agent chances of relapse necessitated the development of new therapeutic approaches [3]
HCV relapse was later cured after receiving daclatasvir, ribavirin, and sofosbuvir combination for 4 weeks
Summary
The annual estimated global bioburden of Hepatitis C virus (HCV) is approximately 130 to 170 million infected people. About 80% of the HCV patients experience chronic hepatitis, cirrhosis, and hepatocellular carcinoma [1, 2]. HCV: hepatitis C virus; DDA: direct acting antiviral agent chances of relapse necessitated the development of new therapeutic approaches [3]. The recent development of the direct acting anti-viral (DAA) drugs has revolutionized the treatment of HCV. This current and standard treatment is efficacious, safe, and welltolerated in a majority of the patients [47].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.